Eli Lilly expects US FDA approval for oral obesity drug in March 2026

By Thomson Reuters Nov 6, 2025 | 3:48 PM

(Reuters) -Eli Lilly expects the U.S. Food and Drug Administration to approve its experimental oral obesity drug, orforglipron, by March 2026, its chief executive said on Thursday.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)

Comments

Leave a Reply Cancel reply

You must be logged in to post a comment.

MLB roundup: Marlins' Sandy Alcantara shuts out White Sox on 93 pitches

1h ago

Crisis contractor for OpenAI, Anthropic eyes a move to combat extremism

3h ago

Singapore charges one more individual with AI chip fraud

4h ago

Central banks' inflation mood puzzle: more judgment than science

3h ago

European shares fall more than 1% as hopes of quick end to Middle East conflict fade

2h ago

India factory activity cooled in March with oil costs rising amid Middle East turmoil, PMI shows

1h ago

Advertise with us »

Evansville | WSTO | hot96.com

Now Playing

HOT 96 | The Tri State's #1 Hit Music Station | Evansville, IN

HOT 96 Music Network

Tell us what you think about the songs we play!

Eli Lilly expects US FDA approval for oral obesity drug in March 2026

Comments

Leave a Reply Cancel reply

Current Weather

7-Day Forecast »

HOT 96 Music Network